020 7713 0990
24 January 2017

The impact of a new treatment for lymphoma can be "significantly enhanced" with immunotherapy, researchers from Manchester University, UK, have reported.

The findings come from a study of the immune system protein TLR7, usually activated in response to viral infection.

The study in laboratory mice found that a TLR7 agonist stimulated NK cells and CD4 helper T-cells during treatment of non-Hodgkin lymphoma with obinutuzumab. But there was little impact on CD8 killer T-cells.

The researchers say their findings, first reported in Leukemia, provide a rationale for clinical testing of the combination.

Obinutuzumab is currently approved for very limited uses in the NHS.

Researcher Professor Tim Illidge said: “We were excited when we discovered that combining obinutuzumab with TLR7 activation significantly enhanced survival of animals with lymphoma by effectively eradicating tumours.

“Clearly, more work needs to be done to assess the impact of this combination on humans – but this study is nevertheless very promising.”

The findings were welcomed by Cancer Research UK.

Dr Justine Alford, from the charity, said: “This study in cells and mice may have found a new way to tap into the power of the immune system and boost a type of immunotherapy for blood cancers.

“Now the challenge will be to develop this potential treatment further and find out if it has similar results in people with cancer.”

Source: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells Leukemia 3 January 2017; doi: 10.1038/leu.2016.352
Link: http://www.nature.com/leu/journal/vaop/ncurrent/abs/leu2016352a.html


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.